Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE trial of EP 104GI in adults with eosinophilic esophagitis
NL-OMON60583Phase 2Active, not recruiting
- Sponsor
- Eupraxia Pharmaceuticals Inc.
- Start
- Feb 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of EP-104GI in eosinophilic esophagitis (EoE) (4 arms), sponsored by Eupraxia Pharmaceuticals Inc. Primary endpoints: Frequency and severity of treatment-emergent adverse events, Change from baseline in clinical safety laboratory measurements and 3 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
EP-104GI
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON60583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60583.